<DOC>
	<DOCNO>NCT00103844</DOCNO>
	<brief_summary>The primary purpose study estimate major cytogenetic response rate BMS-354825 imatinib ( 800 mg/d ) subject chronic phase , Philadelphia chromosome positive , chronic myeloid leukemia ( PH+ CML ) disease resistant imatinib dose 400-600 mg/d .</brief_summary>
	<brief_title>Dasatinib ( BMS-354835 ) Versus Imatinib Mesylate Subjects With Chronic Myeloid Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Philadelphia Chromosome</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>Men woman , 18 year age old . Subjects Chronic Phase Ph+ CML . Subjects treat imatinib dose &gt; 600 mg/day . Subjects develop resistance disease receive imatinib dose 400600 mg/day . Able tolerate imatinib high dose subject receive past . Demonstrate adequate renal hepatic function . Women childbearing potential must negative serum urine pregnancy test , must use adequate method contraception . Women unwilling unable use acceptable method avoid pregnancy entire study period least 1 month least 3 month completion study . Women use prohibited contraceptive method . Women pregnant breastfeeding . Men whose sexual partner woman childbearing potential , unwilling unable use acceptable method avoid pregnancy partner entire study period outline . Prior treatment imatinib dose &gt; 600 mg/day . Subjects previously identify specific BCRABL mutation . Previous diagnosis accelerate phase blast crisis CML . Intolerance imatinib dose . Subjects eligible willing undergo transplantation screen period . Serious uncontrolled medical disorder active infection . Uncontrolled significant cardiovascular disease . Uncontrolled hypertension . Dementia alter mental status . Evidence organ dysfunction . Use imatinib within 7 day . Use interferon cytarabine within 14 day . Use target small molecule anticancer agent within 14 day . Subjects take certain medication accept risk cause Torsades de Pointes . Subjects take medication irreversibly inhibit platelet function anticoagulant . Prior therapy BMS354825 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>Chronic Phase Philadelphia chromosome Positive ( Ph+ ) chronic myeloid leukemia</keyword>
</DOC>